Glaukos Corporation (NYSE:GKOS – Get Free Report) CFO Alex Thurman sold 15,000 shares of the stock in a transaction dated Wednesday, November 18th. The shares were sold at an average price of $236.92, for a total value of $3,553,800.00. Following the completion of the transaction, the chief financial officer directly owned 43,906 shares in the company, valued at $10,402,209.52. This represents a 25.46% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink.
Glaukos Price Performance
Shares of NYSE:GKOS opened at $237.24 on Friday. The company has a debt-to-equity ratio of 0.09, a quick ratio of 4.09 and a current ratio of 4.57. Glaukos Corporation has a 52-week low of $93.78 and a 52-week high of $255.18. The business has a 50-day moving average price of $190.92 and a 200-day moving average price of $150.09.
Glaukos (NYSE:GKOS – Get Free Report) last issued its earnings results on Wednesday, October 28th. The medical instruments supplier reported $0.47 EPS for the quarter, beating analysts’ consensus estimates of ($0.10) by $0.57. Glaukos had a negative return on equity of 0.97% and a negative net margin of 24.60%. The firm had revenue of $211.03 million for the quarter, compared to analyst estimates of $168.04 million. During the same quarter in the prior year, the firm earned ($0.16) earnings per share. Glaukos’s revenue for the quarter was up 58.0% on a year-over-year basis. As a group, equities research analysts predict that Glaukos Corporation will post 0.64 earnings per share for the current year.
Institutional Inflows and Outflows
A number of large investors have recently added to or reduced their stakes in the business. American Century Companies Inc. grew its position in Glaukos by 23.4% in the third quarter. American Century Companies Inc. now owns 6,434 shares of the medical instruments supplier’s stock worth $1,056,000 after acquiring an additional 1,222 shares during the period. Kestra Advisory Services LLC purchased a new stake in Glaukos in the third quarter valued at $200,000. EWA LLC purchased a new stake in Glaukos in the third quarter valued at $218,000. Algert Global LLC lifted its stake in shares of Glaukos by 43.7% in the 3rd quarter. Algert Global LLC now owns 44,361 shares of the medical instruments supplier’s stock valued at $7,284,000 after purchasing an additional 13,490 shares during the last quarter. Finally, Castleark Management LLC acquired a new position in shares of Glaukos in the 3rd quarter valued at $7,812,000. 99.04% of the stock is currently owned by institutional investors and hedge funds.
Wall Street Analysts Forecast Growth
A number of brokerages have recently commented on GKOS. Truist Financial upped their target price on Glaukos from $215.00 to $255.00 and gave the stock a “buy” rating in a research note on Thursday, October 29th. JPMorgan Chase & Co. raised their target price on Glaukos from $200.00 to $240.00 and gave the stock an “overweight” rating in a report on Thursday, October 29th. Wall Street Zen upgraded Glaukos from a “buy” rating to a “strong-buy” rating in a research report on Saturday, November 7th. Mizuho set a $225.00 price objective on Glaukos in a research report on Thursday, October 29th. Finally, BTIG Research increased their price target on shares of Glaukos from $234.00 to $252.00 and gave the stock a “buy” rating in a report on Monday, November 16th. One analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Glaukos presently has an average rating of “Moderate Buy” and a consensus price target of $218.00.
Read Our Latest Stock Report on GKOS
Key Glaukos News
Investors following GKOS have been watching these news items:
- Positive Sentiment: Zacks Research lifted its FY2026 EPS estimate to $0.42 from a forecasted loss of $0.43, and its FY2027 estimate to $1.24 from $0.45. It also raised its FY2028 forecast to $2.24 from $1.70 and increased estimates for multiple quarters. The revisions suggest improved expectations for earnings growth, although they come from one research firm. Glaukos analyst estimates
- Negative Sentiment: COO Joseph Gilliam sold 861 shares for about $215,000 at $250 per share, reducing his stake by 1.19%. The sale may weigh modestly on sentiment, but he still owned 71,602 shares after the transaction. Insider sale report
Glaukos Company Profile
Glaukos Corporation is an ophthalmic medical technology company that develops and commercializes treatments for glaucoma and other eye disorders. Its portfolio includes minimally invasive glaucoma surgery (MIGS) devices, such as the iStent family, and iDose TR, an implant designed to deliver glaucoma medication inside the eye over an extended period. The company also offers products for corneal disorders, including technology used in corneal cross-linking procedures to treat keratoconus and other conditions that weaken the cornea.
Featured Articles
- Five stocks we like better than Glaukos
- MarketBeat Week in Review – 11/16 – 11/20
- Survey Reveals: How Much Would People Pay for Ribeye Before Giving It Up? [2026]
- If NVIDIA Tightens Its Wallet, These 3 Stocks Could Feel It
- 3 Dividend ETFs Offering Steadier Footing in a Shaky Market
Receive News & Ratings for Glaukos Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Glaukos and related companies with MarketBeat.com's FREE daily email newsletter.
